Biomarker & Intervention Discovery

Osteoarthritis

This page lists 10 druggable gene targets, 49 approved or trial-tested drug candidates and 15 recent clinical trials for Osteoarthritis, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

US DALYs1.71MWHO GHE 2021 · all ages
Global DALYs21.16MWHO GHE 2021 · worldwide
US mortality368 deaths/yrWHO GHE 2021
Global mortality5,018 deaths/yrWHO GHE 2021 · worldwide
NIH funding$147MFY2025 · RCDC estimate
Funding levelUnderfunded
Spontaneous remissionStructural progression is essentially universal over 10+ years without intervention; pain fluctuates but functional…
Best-intervention remissionNo cure or disease modification available; total joint replacement (TJR) achieves 85-90% patient satisfaction and…
Gap sizeLarge for pain management vs disease modification (disease modification doesn't exist); moderate for functional…
Primary barrierbiological + practice
Full remission profile →

Remission & chronicity

Spontaneous remission
Structural progression is essentially universal over 10+ years without intervention; pain fluctuates but functional decline is the expected trajectory; no disease-modifying therapy exists as of 2024
Best-intervention remission
No cure or disease modification available; total joint replacement (TJR) achieves 85-90% patient satisfaction and near-elimination of pain but is not disease reversal; weight loss of >10% reduces pain scores ~50% and slows structural progression; exercise therapy comparable to NSAIDs for pain relief
Gap size
Large for pain management vs disease modification (disease modification doesn't exist); moderate for functional outcomes (exercise and weight loss underutilized vs medication)
Primary barrier
biological + practice
OARSI formally petitioned the FDA in 2016 to recognize OA as a serious disease with no cure and no disease-modifying interventions — confirmed in FDA's criteria. Practice gap: NSAIDs have been first-line for >100 years despite long-term evidence of joint damage acceleration and GI/CV risk; exercise consistently outperforms medication in functional outcomes but is rarely 'prescribed'

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ACAN 0ADAMTS5 196COL2A1 3CTNNB1 172IL1B 218IL6 173MMP13 198NGF 9PTGS2 299TNF 277

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ALDUMASTAT ↓ inhibits Mechanistic
AGG-523 ? unclear Mechanistic 560.0 nM (IC50)
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
CHEMBL208009 ↓ inhibits Mechanistic 97.0 nM (Ki)
CHEMBL207305 ↓ inhibits Mechanistic 1900.0 nM (Ki)
CHEMBL230403 ↓ inhibits Mechanistic 20100.0 nM (IC50)
CHEMBL396206 ↓ inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL231000 ↓ inhibits Mechanistic 1600.0 nM (IC50)
CHEMBL230895 ↓ inhibits Mechanistic 1300.0 nM (IC50)
CHEMBL230789 ↓ inhibits Mechanistic 11100.0 nM (IC50)
CHEMBL230894 ↓ inhibits Mechanistic 1300.0 nM (IC50)
CHEMBL230788 ↓ inhibits Mechanistic 1100.0 nM (IC50)
CHEMBL387994 ↓ inhibits Mechanistic 900.0 nM (IC50)
CHEMBL230683 ↓ inhibits Mechanistic 5300.0 nM (IC50)
CHEMBL397040 ↓ inhibits Mechanistic 6700.0 nM (IC50)
CHEMBL397937 ↓ inhibits Mechanistic 6800.0 nM (IC50)
CHEMBL230726 ↓ inhibits Mechanistic 9200.0 nM (IC50)
CHEMBL230725 ↓ inhibits Mechanistic 10000.0 nM (IC50)
CHEMBL396218 ↓ inhibits Mechanistic 5300.0 nM (IC50)
CHEMBL230723 ↓ inhibits Mechanistic 2500.0 nM (IC50)
CHEMBL396217 ↓ inhibits Mechanistic 3200.0 nM (IC50)
CHEMBL230621 ↓ inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL230620 ↓ inhibits Mechanistic 14800.0 nM (IC50)
CHEMBL395985 ↓ inhibits Mechanistic 16200.0 nM (IC50)
CHEMBL230619 ↓ inhibits Mechanistic 4900.0 nM (IC50)
CHEMBL230516 ↓ inhibits Mechanistic 11600.0 nM (IC50)
CHEMBL395503 ↓ inhibits Mechanistic 3500.0 nM (IC50)
CHEMBL230514 ↓ inhibits Mechanistic 1400.0 nM (IC50)
CHEMBL230408 ↓ inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL232565 ↓ inhibits Mechanistic 4200.0 nM (IC50)
CHEMBL391693 ↓ inhibits Mechanistic 9000.0 nM (IC50)
CHEMBL442073 ↓ inhibits Mechanistic 2100.0 nM (IC50)
CHEMBL231740 ↓ inhibits Mechanistic 1100.0 nM (IC50)
CHEMBL232364 ↓ inhibits Mechanistic 2500.0 nM (IC50)
CHEMBL393113 ↓ inhibits Mechanistic 2200.0 nM (IC50)
CHEMBL392264 ↓ inhibits Mechanistic 23200.0 nM (IC50)
CHEMBL233333 ↓ inhibits Mechanistic 9100.0 nM (IC50)
CHEMBL391928 ↓ inhibits Mechanistic 7100.0 nM (IC50)
CHEMBL233132 ↓ inhibits Mechanistic 4200.0 nM (IC50)
CHEMBL393991 ↓ inhibits Mechanistic 4600.0 nM (IC50)

Showing top 40 of 196 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ? unclear Mechanistic
OCRIPLASMIN ? unclear Mechanistic
ALBUTEROL SULFATE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PP1 ↓ inhibits Mechanistic
PF-670462 ↓ inhibits Mechanistic
MPI-0479605 ? unclear Mechanistic
SKF-86002 ↓ inhibits Mechanistic
SB203580 ↓ inhibits Mechanistic
IMATINIB ? unclear Mechanistic
MAPK13-IN-1 ↓ inhibits Mechanistic
BAY1217389 ? unclear Mechanistic
NIROGACESTAT ? unclear Mechanistic
NMS-P715 ? unclear Mechanistic
ACUMAPIMOD ↓ inhibits Mechanistic
EOSIN_Y ? unclear Mechanistic
DILMAPIMOD ↓ inhibits Mechanistic
PRI-724 ↓ inhibits Mechanistic
MW150 ↓ inhibits Mechanistic
COMPOUND 12 [PMID: 22521646] ↓ inhibits Mechanistic
BMS-582949 ↓ inhibits Mechanistic
OSUGACESTAT ? unclear Mechanistic
AZD7624 ↓ inhibits Mechanistic
VANTICTUMAB ? unclear Mechanistic
ANTI-PD-L1 MONOCLONAL ANTIBODY ? unclear Mechanistic
LOSMAPIMOD ↓ inhibits Mechanistic
LENALIDOMIDE ? unclear Mechanistic
NDPPC ↓ inhibits Mechanistic
CELECOXIB ? unclear Mechanistic
TRAMETINIB DIMETHYL SULFOXIDE ? unclear Mechanistic
DORAMAPIMOD ↓ inhibits Mechanistic
CHEMBL:CHEMBL2172378 ? unclear Mechanistic
RECOMBINANT HUMAN ENDOSTATIN ? unclear Mechanistic
TRICIRIBINE ? unclear Mechanistic
TEMSIROLIMUS ? unclear Mechanistic
AZD6703 ↓ inhibits Mechanistic
SAM68 MODULATOR CWP232291 ? unclear Mechanistic
NEFLAMAPIMOD ↓ inhibits Mechanistic
LETROZOLE ? unclear Mechanistic
VX-702 ↓ inhibits Mechanistic
7-HYDROXYSTAUROSPORINE ↓ inhibits Mechanistic
TAK-715 ↓ inhibits Mechanistic
FLUORESCEIN SODIUM ? unclear Mechanistic
PEXMETINIB ↓ inhibits Mechanistic

Showing top 40 of 172 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ASPIRIN ? unclear Mechanistic
MAFOSFAMIDE ? unclear Mechanistic
DIACETYLRHEIN ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LANSOPRAZOLE ? unclear Mechanistic
TILUDRONIC ACID ? unclear Mechanistic
GEVOKIZUMAB ~ modulates Mechanistic
LUTIKIZUMAB ↓ inhibits Mechanistic
CELASTROL ? unclear Mechanistic
CYTARABINE ? unclear Mechanistic
RILONACEPT ↓ inhibits Mechanistic
TT-301 ? unclear Mechanistic
METFORMIN ? unclear Mechanistic
ANTICONVULSANT AGENT ? unclear Mechanistic
ANTIDEPRESSANT AGENT ? unclear Mechanistic
ACITRETIN ? unclear Mechanistic
ERYTHROMYCIN ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
OFLOXACIN ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic
USTEKINUMAB ? unclear Mechanistic
LITHIUM ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
MITOGEN-ACTIVATED PROTEIN KINASE INHIBITOR ? unclear Mechanistic
DRUGSATFDA.NDA:008378 ? unclear Mechanistic
NICARDIPINE ? unclear Mechanistic
GLUCOSAMINE ? unclear Mechanistic
BECLOMETHASONE DIPROPIONATE ? unclear Mechanistic
PAREGORIC ? unclear Mechanistic
CEFACLOR ANHYDROUS ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
MELATONIN ? unclear Mechanistic
PENTAMIDINE ? unclear Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
VERAPAMIL ? unclear Mechanistic
THYROGLOBULIN ? unclear Mechanistic
RISEDRONIC ACID ? unclear Mechanistic
AUTOANTIGEN ? unclear Mechanistic
CDP-484 ↓ inhibits Mechanistic
ETIDRONIC ACID ? unclear Mechanistic

Showing top 40 of 218 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 ↓ inhibits Mechanistic
MRA 003 US ↓ inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB ↓ inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB ↓ inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 ↓ inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB ↓ inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB ↓ inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB ↓ inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CURCUMIN ? unclear Mechanistic
REBIMASTAT ↓ inhibits Mechanistic
DOXYCYCLINE CALCIUM ↓ inhibits Mechanistic
APRATASTAT ↓ inhibits Mechanistic
PRINOMASTAT ? unclear Mechanistic 1.5 nM (IC50)
DOXYCYCLINE ANHYDROUS ↓ inhibits Mechanistic
CTS-1027 ↓ inhibits Mechanistic 2.0 nM (IC50)
ILOMASTAT ? unclear Mechanistic
DOXYCYCLINE HYCLATE ? unclear Mechanistic
DOXYCYCLINE ? unclear Mechanistic
CHEMBL348210 ↓ inhibits Mechanistic 3.0 nM (IC50)
CHEMBL80814 ↓ inhibits Mechanistic 2.0 nM (IC50)
CHEMBL346624 ↓ inhibits Mechanistic 0.7 nM (IC50)
CHEMBL276119 ↓ inhibits Mechanistic 2.0 nM (IC50)
CHEMBL78934 ↓ inhibits Mechanistic 5.0 nM (IC50)
CHEMBL78369 ↓ inhibits Mechanistic 1.0 nM (IC50)
CGS-27023A ↓ inhibits Mechanistic 8.0 nM (IC50)
CHEMBL151591 ↓ inhibits Mechanistic 3.0 nM (IC50)
CHEMBL80453 ↓ inhibits Mechanistic 4.0 nM (IC50)
CHEMBL312432 ↓ inhibits Mechanistic 6.0 nM (IC50)
CHEMBL150655 ↓ inhibits Mechanistic 0.2 nM (IC50)
CHEMBL306617 ↓ inhibits Mechanistic 2.0 nM (IC50)
CHEMBL79111 ↓ inhibits Mechanistic 2.0 nM (IC50)
CHEMBL78798 ↓ inhibits Mechanistic 1.0 nM (IC50)
CHEMBL440355 ↓ inhibits Mechanistic 0.5 nM (IC50)
CHEMBL80969 ↓ inhibits Mechanistic 2.0 nM (IC50)
CHEMBL78909 ↓ inhibits Mechanistic 1.0 nM (IC50)
CHEMBL76137 ↓ inhibits Mechanistic 3.0 nM (IC50)
CHEMBL310340 ↓ inhibits Mechanistic 1.4 nM (IC50)
CHEMBL150027 ↓ inhibits Mechanistic 0.4 nM (IC50)
CHEMBL346442 ↓ inhibits Mechanistic 0.2 nM (IC50)
CHEMBL76836 ↓ inhibits Mechanistic 3.0 nM (IC50)
CHEMBL150077 ↓ inhibits Mechanistic 0.3 nM (IC50)
CHEMBL357796 ↓ inhibits Mechanistic 8.0 nM (IC50)
CHEMBL312429 ↓ inhibits Mechanistic 2.0 nM (IC50)
CHEMBL78549 ↓ inhibits Mechanistic 1.0 nM (IC50)
CHEMBL78508 ↓ inhibits Mechanistic 2.0 nM (IC50)
CHEMBL80732 ↓ inhibits Mechanistic 2.0 nM (IC50)
CHEMBL309311 ↓ inhibits Mechanistic 1.0 nM (IC50)
CHEMBL151399 ↓ inhibits Mechanistic 4.0 nM (IC50)

Showing top 40 of 198 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MEDI-578 ↓ inhibits Mechanistic
CERE-110 ? unclear Mechanistic
FASINUMAB ↓ inhibits Mechanistic
TANEZUMAB ↓ inhibits Mechanistic
FRUNEVETMAB ~ modulates Mechanistic
FULRANUMAB ↓ inhibits Mechanistic
BEDINVETMAB ~ modulates Mechanistic
PG-110 ↓ inhibits Mechanistic
CHEMBL1397270 ↓ inhibits Mechanistic 1000.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN ↓ inhibits Mechanistic 102.0 nM (IC50)
INDOMETHACIN SODIUM ↓ inhibits Mechanistic
DARBUFELONE ? unclear Mechanistic
MEFENAMIC ACID ↓ inhibits Mechanistic
MECLOFENAMATE SODIUM ↓ inhibits Mechanistic
DICLOFENAC SODIUM ↓ inhibits Mechanistic
CAPECITABINE ? unclear Mechanistic
PIRPROFEN ↓ inhibits Mechanistic
ESFLURBIPROFEN ↓ inhibits Mechanistic
SULFASALAZINE ↓ inhibits Mechanistic
BROMFENAC ? unclear Mechanistic
IBUPROFEN, SODIUM SALT ↓ inhibits Mechanistic
ALOXIPRIN ↓ inhibits Mechanistic
TENOXICAM ? unclear Mechanistic
FLURBIPROFEN ↓ inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
DEXKETOPROFEN ↓ inhibits Mechanistic
ETORICOXIB ↓ inhibits Mechanistic
LUMIRACOXIB ↓ inhibits Mechanistic
SUPROFEN ↓ inhibits Mechanistic
NS-398 ? unclear Mechanistic
NABUMETONE ↓ inhibits Mechanistic
URSOLIC ACID ? unclear Mechanistic
IBUPROFEN LYSINE ↓ inhibits Mechanistic
ACECLOFENAC ↓ inhibits Mechanistic
IBUFENAC ↓ inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
DIFLUNISAL ↓ inhibits Mechanistic
BALSALAZIDE DISODIUM ↓ inhibits Mechanistic
VACCINE ? unclear Mechanistic
KETOROLAC TROMETHAMINE ↓ inhibits Mechanistic
BENZYDAMINE HYDROCHLORIDE ↓ inhibits Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
NAPROXCINOD ↓ inhibits Mechanistic
IGURATIMOD ↓ inhibits Mechanistic
ETODOLAC ↓ inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM ↓ inhibits Mechanistic
ROFECOXIB ↓ inhibits Mechanistic 530.0 nM (IC50)

Showing top 40 of 299 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
NERELIMOMAB ↓ inhibits Mechanistic
CROMOLYN SODIUM ? unclear Mechanistic
PLACULUMAB ↓ inhibits Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
GENTAMICIN ? unclear Mechanistic
GOLIMUMAB ↓ inhibits Mechanistic
BUPIVACAINE ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic 85000.0 nM (IC50)
BENZO[E]PYRENE ? unclear Mechanistic
THALIDOMIDE ? unclear Mechanistic
PYRAZINAMIDE ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
LENERCEPT ↓ inhibits Mechanistic
ADALIMUMAB ↓ inhibits Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
LENABASUM ? unclear Mechanistic
MAGNESIUM SULFATE ANHYDROUS ? unclear Mechanistic
PICIBANIL ? unclear Mechanistic
FLUOCINOLONE ACETONIDE ? unclear Mechanistic
MILTEFOSINE ? unclear Mechanistic
HOMIDIUM BROMIDE ? unclear Mechanistic
OZORALIZUMAB ↓ inhibits Mechanistic
PEGSUNERCEPT ↓ inhibits Mechanistic
CERTOLIZUMAB PEGOL ↓ inhibits Mechanistic
THERAPEUTIC HORMONE ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
FOLIC ACID ? unclear Mechanistic
ABBV-257 ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
COVA322 ? unclear Mechanistic
HYDROXYCHLOROQUINE ? unclear Mechanistic
CERTOLIZUMAB ? unclear Mechanistic
AN0128 ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SORAFENIB ? unclear Mechanistic

Showing top 40 of 277 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Osteoarthritis: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT07901790 Phase: N/A Started: 2026-09-03

This multicenter, prospective, randomized, active-controlled, single-blind (assessor-blinded) clinical trial aims to evaluate the efficacy and safety of intra-articular injection of autologous adipose-derived mesenchymal stem cells (ADMSCs) compared with active comparator hyaluronic acid (HA) in pat...

NCT07736352 Phase: N/A Started: 2026-07-30

The goal of this clinical trial is to determine the appropriate Bispectral Index (BIS) range and propofol effect-site concentration required to maintain adequate anesthesia depth during total intravenous anesthesia (TIVA) combined with midazolam, dexmedetomidine, or esketamine in patients undergoing...

NCT07902128 Phase: 1 Started: 2025-12-10

Approximately 25 participants aged 18-70 years, with knee pain rated 4-7 on a 10-point visual analogue scale (VAS) and a disease duration of 6 months to 10 years, will be enrolled. The study has two parts. In Part 1, participants receive a single intra-articular injection of 1.0 mL, 1.5 mL or 2.0 mL...

NCT07225829 Phase: 2 Started: 2025-06-17

This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in: * patients between 40 and 80 years of age, * with synovitis and grade 2 to 4 osteoarthr...

NCT07870967 Phase: N/A Started: 2027-03

This randomized, controlled, double-blind, three-arm parallel clinical trial will evaluate the efficacy and safety of undenatured type II collagen products on joint pain in adults diagnosed with knee osteoarthritis. Participants will be randomized to Nuvicol II (nuvicol® II), Nuvicol SII (nuvicol® S...

NCT03825965 Phase: 3 Started: 2023-05-03

Each year, approximately 75,000 Canadians undergo knee replacement surgery, and up to 25% develop persistent post-surgical pain. Persistent post-surgical pain is associated with depression, anxiety, unemployment, and reduced quality of life. Chronic pain after surgery is often managed with opioid th...

NCT07875543 Phase: 2 Started: 2024-01-01

The goal of this clinical trial is to compare the therapeutic effects of lyophilized platelet-rich plasma lysate and dextrose prolotherapy in patients with knee osteoarthritis (OA). The main questions it aims to answer are: * Does lyophilized platelet-rich plasma lysate improve pain, physical functi...

NCT07759336 Phase: 4 Started: 2026-09-15

The goal of this clinical trial is to examine the effects of duloxetine on walking ability and physical activity in patients with knee osteoarthritis. Researchers will compare duloxetine to a placebo (a look-alike substance that contains no drug) to see if duloxetine works to improve walking ability...

NCT07338266 Phase: 1 Started: 2026-01-22

This study aims to understand the safety, drug concentration and distribution of an intra-articular injectable formulation of celecoxib, AVD275, in patients with knee osteoarthritis. One single injection at three different doses of the drug will be studied in a sequential order, and each participant...

NCT07226258 Phase: 3 Started: 2025-11-07

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 for the Treatment of Knee Pain in Patients with Osteoarthritis of the Knee.

NCT07219771 Phase: 3 Started: 2025-10-14

This is a multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of intra-articular administration of PTP-001 (MOTYS) for the treatment of knee osteoarthritis. The purpose of the trial is to evaluate the efficacy, safety, and tolerability of a single intr...

NCT05147675 Phase: 1 Started: 2022-12-01

This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously and intraarticularly for the treatment of Osteoarthritis.

NCT06096259 Phase: 2 Started: 2024-05-06

This study is being done to find out if metformin is effective at reducing pain by delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament (ACL) reconstruction. This research study will compare metformin to placebo. The placebo tablet looks exactly like metformin,...

NCT05997238 Phase: 4 Started: 2023-04-25

To evaluate the efficacy and safety of different doses of triamcinolone for local infiltration analgesia during total knee replacement

NCT07580716 Phase: 2 Started: 2026-05-01

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).


Agents Found By Disease-Level Search

Searched directly from “Osteoarthritis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

49 agents shown (approved or with trial evidence) — 48 not found by the gene-target search above.

transient immune-modulationNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT05835895 NCT05835895

FX006 32 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02762370

TCA IR 40 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02762370

DELTA Revision acetabular cupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06359301

Ketoprofen Topical Patch , 20%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00365586

MPact CupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03897595

YYD302 2mlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02965495

YYD302 3mlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02965495

GNSC-001NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05835895

Fit & Strong!NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04536727

Wait listNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04536727

tai chiNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03660254

Corticosteroid injection (CSI)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07217405

stem cell injectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01499056

Autologous cell therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03984461

Operative (partial arthroscopy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00549172

Conservative (diagnostic arthroscopy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00549172

chondroitin sulfateNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02079727

celecoxib

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02079727

Non-image-based Computer-Assisted Navigation with Bone MorphingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07574775

P.F.C. Sigma KneeNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00734019

Sodium Hyaluronate (Hyalgan)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01267214

Osteotomy aloneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01267214

Medacta GMK Sphere® Medial Knee ProsthesisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02501733

TriathlonNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05842538

Total knee replacement with the ROCC® knee prosthesisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02127619

Vitamin DNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01176344

Total Hip ArthroplastyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06640764

OraVescent FentanylNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00343733

Aquamid reconstructionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03060421

Stem Cell Support FormulaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04661267

Zimmer Patient specific instrumentsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02096393

Standard instrumentationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02096393

barbed sutureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03031314

standard sutureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03031314

Tapentadol (CG5503) Extended Release (ER)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00487435

Synvisc-One (hylan G-F 20)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01618708

Vivacit-E LinerNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03226808

Liposomal bupivacaineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02762071

Interscalene Nerve BlockNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02762071

BioPolyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06915363

Electrotherapy groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04588558

Evicel fibrin sealantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01235715

Traumeel® / Zeel® Injectable SolutionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01887678

injection of Filtered Autologous Adipose TissueNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04567732

lorecivivint (SM04690)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02536833

ESWTNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04243135

Nudge interventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07330492

CATALYSTEMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06564636

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.